Ratio Therapeutics Secures $70 Million Funding for Radiotherapeutics Growth and Innovation
Ratio Therapeutics, Inc., a pivotal player in the pharmaceutical industry focused on developing cutting-edge radiopharmaceuticals for cancer therapy, has announced the successful closing of a $70 million Series C funding round. This significant financial boost from notable investors including Duquesne Family Office and Bristol Myers Squibb, along with new backers like Catalio Capital Management and Eli Lilly and Company, brings the total capital raised by Ratio to over $240 million. The influx of funds will support Ratio's aggressive growth strategy as the company moves forward with clinical trials and expands its manufacturing capabilities.
The proceeds from this financing are earmarked for advancing Ratio's ongoing ATLAS study, which is evaluating its primary radiotherapeutic asset, Ac-225 RTX-2358, particularly in the treatment of advanced sarcomas. This pivotal trial is crucial as it seeks to establish the efficacy and safety of Ratio's promising therapies in real-world clinical settings. Additionally, the funding will facilitate the introduction of the next-generation radioligand therapy candidate into clinical practice, broadening the spectrum of therapeutic options available for cancer treatment.
In a strategic move, Ratio Therapeutics plans to extend its discovery pipeline into new, high-value oncology targets. This expansion aims to address significant unmet medical needs in various tumor types, thereby enhancing its portfolio's market potential. The investment will not only enhance research and development but will also solidify Ratio's proprietary technology in radiopharmaceuticals, allowing the company to scale its manufacturing capabilities in anticipation of future commercial demand.
"This financing underscores the confidence our investors have in our progress and the future opportunities we see ahead," stated Dr. Jack Hoppin, the CEO of Ratio Therapeutics. He emphasized that this funding is essential for progressing both the ATLAS trial and preparing for subsequent Investigational New Drug (IND) applications. The trust shown by investors is a testament to Ratio's dedication to advancing radiopharmaceutical technology to improve patient outcomes.
Dr. Sue Meng from Duquesne Family Office remarked on Ratio's leadership in the realm of radiopharmaceutical innovation, noting the company's substantial achievements in hitting critical clinical milestones and forging deep strategic partnerships. The success of their manufacturing infrastructure underscores the operational capacity required for this specialized field of medicine.
About Ratio Therapeutics: Based in Boston, Ratio Therapeutics is at the forefront of clinical-stage pharmaceutical development, specializing in the engineering of radiopharmaceuticals aimed at maximizing therapeutic index and developing premier cancer treatments. Their flagship program, Ac-225 RTX-2358, is currently undergoing trials in the ATLAS Phase 1/2 study. The company's innovative pipeline also includes next-generation GRPR programs, additional mono- and bispecific radioligand therapies, and imaging assets, facilitated by their proprietary Trillium pharmacokinetic tuning technology and Macropa chelator platform.
Beyond innovation, Ratio Therapeutics boasts a versatile manufacturing model that combines their internally developed capabilities in Utah with external partnerships and diverse isotope supplies, ensuring a robust and reliable production process. For further details on Ratio Therapeutics and its exciting pipeline, visit www.ratiotx.com, and follow the company on Twitter and LinkedIn for the latest updates.
The proceeds from this financing are earmarked for advancing Ratio's ongoing ATLAS study, which is evaluating its primary radiotherapeutic asset, Ac-225 RTX-2358, particularly in the treatment of advanced sarcomas. This pivotal trial is crucial as it seeks to establish the efficacy and safety of Ratio's promising therapies in real-world clinical settings. Additionally, the funding will facilitate the introduction of the next-generation radioligand therapy candidate into clinical practice, broadening the spectrum of therapeutic options available for cancer treatment.
In a strategic move, Ratio Therapeutics plans to extend its discovery pipeline into new, high-value oncology targets. This expansion aims to address significant unmet medical needs in various tumor types, thereby enhancing its portfolio's market potential. The investment will not only enhance research and development but will also solidify Ratio's proprietary technology in radiopharmaceuticals, allowing the company to scale its manufacturing capabilities in anticipation of future commercial demand.
"This financing underscores the confidence our investors have in our progress and the future opportunities we see ahead," stated Dr. Jack Hoppin, the CEO of Ratio Therapeutics. He emphasized that this funding is essential for progressing both the ATLAS trial and preparing for subsequent Investigational New Drug (IND) applications. The trust shown by investors is a testament to Ratio's dedication to advancing radiopharmaceutical technology to improve patient outcomes.
Dr. Sue Meng from Duquesne Family Office remarked on Ratio's leadership in the realm of radiopharmaceutical innovation, noting the company's substantial achievements in hitting critical clinical milestones and forging deep strategic partnerships. The success of their manufacturing infrastructure underscores the operational capacity required for this specialized field of medicine.
About Ratio Therapeutics: Based in Boston, Ratio Therapeutics is at the forefront of clinical-stage pharmaceutical development, specializing in the engineering of radiopharmaceuticals aimed at maximizing therapeutic index and developing premier cancer treatments. Their flagship program, Ac-225 RTX-2358, is currently undergoing trials in the ATLAS Phase 1/2 study. The company's innovative pipeline also includes next-generation GRPR programs, additional mono- and bispecific radioligand therapies, and imaging assets, facilitated by their proprietary Trillium pharmacokinetic tuning technology and Macropa chelator platform.
Beyond innovation, Ratio Therapeutics boasts a versatile manufacturing model that combines their internally developed capabilities in Utah with external partnerships and diverse isotope supplies, ensuring a robust and reliable production process. For further details on Ratio Therapeutics and its exciting pipeline, visit www.ratiotx.com, and follow the company on Twitter and LinkedIn for the latest updates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.